Survival After Lymph Node Dissection, Radiotherapy, and Combined Treatment in Sentinel Node–Positive Stage IIIA Merkel Cell Carcinoma: A Systematic Review and Meta-analysis

Description

Supplemental Data for the Systematic Review article and meta-analysis: Survival After Lymph Node Dissection, Radiotherapy, and Combined Treatment in Sentinel Node–Positive Stage IIIA Merkel Cell Carcinoma: A Systematic Review and Meta-analysis Content Supplementary Figure 1. 1-year and 3-year survival rate after CLND versus no CLND. Supplementary Figure 2. 1-year and 3-year survival rate after radiotherapy versus no radiotherapy. Supplementary Figure 3. 5-year survival rates after CLND versus no CLND, RTX versus not RTX and from the network meta-analysis (NMA). Supplementary Figure 4. Risk of bias assessment. Supplementary Figure 5. Network meta‐analysis comparing RTX alone, and complete lymph node dissection and radiotherapy (CLND + RTX) with CLND alone regarding 1-year (a) and 3-year (b) OS. Supplementary Figure 6. Leave-one-out sensitivity analyses. Supplementary Table 1. Summary of studies evaluating progression-free survival (PFS), nodal recurrence–free survival (NRFS), and distant metastasis–free survival (DMFS) in patients with Merkel cell carcinoma (MCC). Supplementary Table 2. Overview of study characteristics, patient populations, and outcome definitions across included studies.

Institutions

• TUM Klinikum

  Bavaria, Munich
• LMU Klinikum

  Bavaria, Munich

Categories

Licence